Compare Medpace Holdings Inc (MEDP) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Sony Group Corp — how do they compare? Medpace Holdings Inc trades at $599.9 (market cap $16.90B), while Sony Group Corp trades at $23.49 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 8.2× Medpace Holdings Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SONY | |
|---|---|---|
Market Cap | $16.90B | $138.43B |
Sector | Technology | Technology |
52-Week High | $620.59 | $30.26 |
52-Week Low | $393.42 | $19.32 |
Enterprise Value | $16.52B | $136.35B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Sony's stock is trading at $23.48, down 1.43% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong cash flow of $1.07 trillion in 2025 and beat EPS estimates in two of the last three quarters, though Q1 2026 was a miss. Recent news highlights success from Spider-Man: Brand New Day and a joint venture with TSMC for image sensors, signaling growth in entertainment and technology segments.
The investment outlook is positive, driven by analyst consensus favoring a buy rating (68.75%) and potential upside from blockbuster films and sensor innovation. Key risks include a projected net loss in 2026, competitive pressures in gaming, and currency volatility. Fundamentals show solid revenue but margin compression, requiring careful monitoring of profit trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
